Akari Therapeutics Q2 net loss widens to $4.8 million; raises $8.6 million gross
Akari Therapeutics reported second quarter 2026 results, with a net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending rose to $2.1 million from $0.7 million. The company raised about $8.6 million in gross financing during the quarter, and cash totaled $7.7 million as of June 30, 2026, which it says supports its AKTX-101 development toward a Phase 1 trial planned for mid-2027.
Key points
- Net loss for Q2 2026 was $4.8 million, compared with $1.9 million in Q2 2025.
- R&D expenses were $2.1 million, up from $0.7 million; G&A expenses were $2.5 million, flat year over year.
- Financing totaled about $8.6 million gross ($5.5 million private placement plus $3.1 million from warrant exercises), or about $8.0 million net.
- Cash was $7.7 million at June 30, 2026, up from $5.2 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.